ClinicalTrials.gg
RecruitingNCT03137355Updated Dec 1, 2023

The International Registry for Leigh Syndrome

An observational study in Leigh Syndrome, Leigh Disease and Leigh's Necrotizing Encephalopathy, sponsored by The University of Texas Health Science Center, Houston. Recruiting at 1 site in United States. Open to participants aged 0 Days to 100 Years. Per ClinicalTrials.gov, last updated 2023-12-01.

Sponsored by The University of Texas Health Science Center, Houston · Observational

How we know

From the registry’s dates

  • Started Jun 2015; still recruiting 11 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Other
Enrollment
200
Ages
0 Days to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Leigh Disease with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Leigh Disease · United States.

Started
2015
with 1 other
Observational
6 of 14
5 open now
Registered
10th of 14
by date
Lead sponsor
1 of 14
The University of Texas Health Science Center, Houston

Among the 14 studies in Leigh Disease with a site in United States, this one is one of 2 that started in 2015, is one of 6 observational ones, and was the 10th registered.

Leigh Disease

20 studies on the registry are indexed under Leigh Disease; 9 are open to participants now.

Browse Leigh Disease studies →

Open to participants now

6 of the 14 studies in Leigh Disease with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Leigh Disease studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 0 Days to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Leigh Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to develop a database containing clinical and laboratory information for patients with Leigh syndrome. The goal is to provide a greater understanding of Leigh syndrome allowing further characterization of this disease.

Read the detailed description

Leigh syndrome, also known as juvenile sub-acute necrotizing encephalopathy, is a progressive neurodegenerative disorder associated with dysfunction of mitochondrial oxidative phosphorylation (OXPHOS). First described in 1951 by British neuropsychiatrist Archibald Denis Leigh, the condition has evolved from a post mortem diagnosis to a clinical entity with characteristic radiologic and laboratory findings.

Leigh syndrome is a rare and heterogeneous disease, finding a substantial number of patients to study is difficult. The lack of natural history data in Leigh syndrome and the small number of patients included in clinical reports thus far has limited the ability to fully comprehend the progression of this disease and assess prognostic factors. A Leigh syndrome database will help improve our understanding of this rare disease leading to an improved ability to predict outcomes and/or improve treatment paradigms. Collecting natural history data on Leigh syndrome and integrating this information into a database will be useful in understanding the course of the disease and identifying trends.

03

Conditions studied

  • Leigh Syndrome
  • Leigh Disease
  • Leigh's Necrotizing Encephalopathy
  • Subacute Necrotizing Encephalomyopathy
  • Subacute Necrotizing Encephalomyelopathy

Browse trials for

Keywords

  • Leigh Syndrome
  • Leigh Disease
  • Leigh's Necrotizing Encephalopathy
  • Subacute Necrotizing Encephalomyelopathy
  • Subacute Necrotizing Encephalomyopathy
04

Who can participate

Ages eligible
0 Days to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

People with a diagnosis of Leigh syndrome.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All participants with a diagnosis of Leigh syndrome will be invited to participate

Exclusion criteria

Exclusion Criteria:

  • People without Leigh syndrome
05

Study design

Observational model
Case-only
Time perspective
Other
Enrollment
200 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes

Groups and cohorts

  • Leigh syndrome

    All people diagnosed with Leigh syndrome.

06

What researchers measure

Primary outcomes

  1. Phenotypical characteristics of Leigh syndrome

    The goal of this project is to collect longitudinal data on the natural history of Leigh syndrome.

    Time frame: 10 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2015 (actual). Primary completion is estimated for Jun 2030, 180 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2017
First posted
May 2, 2017
StartActual
Jun 17, 2015
Primary completionEst.
Jun 17, 2030
CompletionEst.
Jun 17, 2030
Last update
Dec 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03137355
Responsible party
Mary Kay Koenig (Professor, The University of Texas Health Science Center, Houston) — Principal investigator
First posted
May 2, 2017
Start date
Jun 17, 2015
Primary completion
Jun 17, 2030 (estimated)
Completion
Jun 17, 2030 (estimated)
Last update
Dec 1, 2023

Study contacts

Mary Kay Koenig, MD
Contact
leigh@uth.tmc.edu
713-500-7164
William Guerra
Contact
leigh@uth.tmc.edu
713-500-7164
Mary Kay Koenig, MD
principal investigator · The University of Texas Health Science Center, Houston

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion